Agilent Technologies (NYSE:A) Expands Cancer Diagnostic Kit Indications In EU For NSCLC And Melanoma
Agilent Technologies (NYSE:A) recently achieved EU IVDR approval for two new indications of its PD-L1 IHC 28-8 pharmDx kit, expanding treatment options for early-stage NSCLC and advanced melanoma.
Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications
Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic ...
Agilent lowers annual revenue forecast on soft demand for medical equipment
Medical equipment maker Agilent lowered its annual revenue forecast on Wednesday, as it expects soft demand for its medical tools and equipment from smaller biotech companies.
PFAS Testing Market worth US$969.5 million by 2030 with 14.5% CAGR | MarketsandMarkets™
The global PFAS Testing Market, valued at US$379.2 million in 2023, is forecasted to grow at a robust CAGR of 14.5%, reaching ...
Agilent price target lowered to $138 from $145 at Barclays
Barclays analyst Luke Sergott lowered the firm’s price target on Agilent (A) to $138 from $145 to adjust for the reset in market valuations in ...
Analysts Offer Insights on Healthcare Companies: Agilent (A) and C4 Therapeutics (CCCC)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Agilent (A – Research Report) and C4 ...